Nalaganje...
Definition and management of ruxolitinib treatment failure in myelofibrosis
Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF). Several other JAK inhibitors are in development with some currently undergoing phase-3 clinical trial testing....
Shranjeno v:
| izdano v: | Blood Cancer J |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4315890/ https://ncbi.nlm.nih.gov/pubmed/25501025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.84 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|